0.38
-0.011(-2.83%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.42 |
| Day High | 0.42 |
| Day Low | 0.37 |
| 52-Week High | 1.53 |
| 52-Week Low | 0.22 |
| Volume | 190,480 |
| Average Volume | 1.94M |
| Market Cap | 15.85M |
| PE | -0.79 |
| EPS | -0.48 |
| Moving Average 50 Days | 0.29 |
| Moving Average 200 Days | 0.49 |
| Change | -0.01 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $21.61 as of March 04, 2026 at a share price of $0.378. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 1 year ago, it would be worth $307.48 as of March 04, 2026 at a share price of $0.378.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
GlobeNewswire Inc.
Mar 02, 2026 1:30 PM GMT
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pot
FibroBiologics to Present at the BIO Investment & Growth Summit
GlobeNewswire Inc.
Feb 26, 2026 1:30 PM GMT
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Feb 24, 2026 9:30 PM GMT
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed payments of outstanding debtHOUSTON, Feb. 24, 2